Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Rituximab in Relapsed/Refractory Follicular NHL
NCT00848328Phase 2Terminated
- Sponsor
- University of California, Davis
- Start
- Aug 2008
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in follicular lymphoma (FL) and small lymphocytic lymphoma (SLL), sponsored by University of California, Davis. Primary endpoint: Response Rate (CR, near CR, PR, or SD) at 4 months. Started Aug 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00848328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848328.